May 1, 2008- Sepracor Inc. (Nasdaq: SEPR) announced it has signed a technology license and development agreement with Arrow International Limited (Arrow), a European company, for know-how and intellectual property rights related to stable sterile steroid suspension formulations as well as other applicable nebule technology for the use in developing ciclesonide, a corticosteroid, in an inhalation solution. The agreement facilitates enhanced development of Sepracor's ciclesonide stand-alone product for the treatment of asthma as well as a planned ciclesonide/ BROVANA(R) brand arformoterol tartrate Inhalation Solution combination product for the treatment of COPD, and includes Arrow's "U-Bend" packaging technology, which allows increased accuracy in dosing through a novel U-Bend ampule design... Sepracor's Press Release -
Showing posts with label Arrow International Limited. Show all posts
Showing posts with label Arrow International Limited. Show all posts
May 19, 2008
Sepracor & Arrow : Global License and Development Agreement Covering Technology to Enhance Ciclesonide and BROVANA Franchises
May 1, 2008- Sepracor Inc. (Nasdaq: SEPR) announced it has signed a technology license and development agreement with Arrow International Limited (Arrow), a European company, for know-how and intellectual property rights related to stable sterile steroid suspension formulations as well as other applicable nebule technology for the use in developing ciclesonide, a corticosteroid, in an inhalation solution. The agreement facilitates enhanced development of Sepracor's ciclesonide stand-alone product for the treatment of asthma as well as a planned ciclesonide/ BROVANA(R) brand arformoterol tartrate Inhalation Solution combination product for the treatment of COPD, and includes Arrow's "U-Bend" packaging technology, which allows increased accuracy in dosing through a novel U-Bend ampule design... Sepracor's Press Release -
Subscribe to:
Comments (Atom)
